Estrella Immunopharma, Inc. (ESLA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Estrella Immunopharma, Inc. (ESLA) closed at USD 0.32 on 2026-10-14, a change of -87.1 % over the past year, with a market capitalization of USD 23.28M.

Estrella Immunopharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Estrella Immunopharma, Inc. key figures

Previous close

USD 0.32 (2026-10-14)

1-year change

-87.1 %

Market cap

USD 23.28M

Enterprise value

USD 23.13M

P/E ratio (trailing)

-1.25

P/E ratio (forward)

-1.67

EPS (trailing)

-0.43

EPS (forward)

-0.32

PEG ratio

n/a

Price to book

-3.09

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.19

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Estrella Immunopharma, Inc. and compare it with other stocks.